Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...

The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease. In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked ...

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in ...

Alkeus Pharmaceuticals, Inc., announced additional data from its Phase 2 clinical SAGA study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In this trial patients ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

Chengdu Origen Biotechnology Co, Ltd. And Vanotech Ltd. recently announced the dosing of the first patient in the VAN-2401 multi-center phase 1 clinical trial (NCT06825858). 1 The VAN-2401 clinical ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...